10-KPeriod: FY2019

Medtronic plc Annual Report, Year Ended Apr 26, 2019

Filed June 21, 2019For Securities:MDT

Summary

Medtronic plc's 2019 10-K filing reveals a company focused on global health through its diverse medical technology offerings. The company operates across four key segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. These segments provide a broad range of products and services aimed at alleviating pain, restoring health, and extending life for millions worldwide. Financially, the company demonstrated a modest increase in net sales for fiscal year 2019, driven by strong performance in its Restorative Therapies and Diabetes segments, although this was partially offset by a divestiture within the Minimally Invasive Therapies Group. Medtronic continues to prioritize its three growth strategies: Therapy Innovation, Globalization, and Economic Value, evident in its ongoing investment in research and development and its expansion into emerging markets. The company also maintains a strong commitment to returning capital to shareholders through share repurchases and dividends, supported by robust operating cash flow.

Financial Highlights

55 data points
Beta

Revenue

$30.56B

70.0% Gross Margin

Net Income

$4.65B

15.2% Net Margin

EPS (Diluted)

$3.41

Total Assets

$89.69B

Cash & Equivalents

$4.39B

Free Cash Flow

$5.87B

Financial Statements
Beta
Revenue$30.56B
Cost of Revenue$9.15B
Gross Profit$21.40B
SG&A Expenses$10.42B
Operating Income$6.27B
Interest Expense$1.44B
Net Income$4.65B
EPS (Basic)$3.44
EPS (Diluted)$3.41
Shares Outstanding (Basic)1.35B
Shares Outstanding (Diluted)1.36B

Key Highlights

  • 1Medtronic operates through four primary segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes, offering a wide range of medical technologies.
  • 2Net sales saw a modest increase in fiscal year 2019, driven by growth in the Restorative Therapies and Diabetes segments, though impacted by a divestiture in the Minimally Invasive Therapies Group.
  • 3The company is actively pursuing its growth strategies: Therapy Innovation, Globalization (with emerging markets growing 6% in FY19), and Economic Value, focusing on value-based healthcare solutions.
  • 4Research and Development expenses remained substantial, reflecting a commitment to innovation, with R&D spending at $2.3 billion for fiscal years 2019 and 2018.
  • 5Medtronic maintained a strong liquidity position, with $4.4 billion in cash and cash equivalents and $5.5 billion in current investments at the end of fiscal year 2019.
  • 6The company actively returned capital to shareholders, with an authorized share repurchase program of $11.0 billion, having utilized approximately $3.8 billion by April 2019.
  • 7Medtronic's balance sheet shows significant goodwill ($39.9 billion) and other intangible assets ($20.5 billion), primarily resulting from past acquisitions and reflecting strategic investments in technology and brands.

Frequently Asked Questions

Medtronic operates through four principal operating and reportable segments: the Cardiac and Vascular Group, the Minimally Invasive Therapies Group, the Restorative Therapies Group, and the Diabetes Group. These segments cover a broad spectrum of medical technologies and solutions.

For the fiscal year ended April 26, 2019, Medtronic reported net sales of $30.56 billion, an increase of 2% compared to the previous year. Net income attributable to Medtronic was $4.63 billion, a significant increase from $3.10 billion in fiscal year 2018, primarily due to a large tax charge in FY18 related to U.S. tax reform.

Medtronic's growth is driven by three key strategies: Therapy Innovation (launching meaningful therapies and procedures), Globalization (expanding access in emerging markets), and Economic Value (offering services and solutions to improve outcomes and efficiency). The company invests heavily in R&D and strategic acquisitions to support these strategies.

Medtronic identified several key risks, including intense competition in the medical technology market, potential disruptions in supply and manufacturing, the impact of stringent government regulations and adverse regulatory actions, the need to protect intellectual property, product quality issues leading to liability claims, and changes in healthcare policies and reimbursement. Risks associated with global operations, such as currency fluctuations and trade regulations, were also noted.